| | |
HIV-infected patients
|
|---|
| |
Control group
|
Non-HCV co-infected group
|
HCV co-infected group
|
|---|
| |
( n = 102)
|
VL < 40 copies/mL
|
VL > 40 copies/mL
|
VL < 40 copies/mL
|
VL > 40 copies/mL
|
|---|
| | |
(n = 47)
|
(n = 29)
|
(n = 67)
|
(n = 48)
|
|---|
|
FASN, μg/L
|
3.36 (0.92)
|
5.83 (1.34) a
|
5.08 (1.74) *
|
12.69 (2.01) c
|
14.41 (2.91) c
|
|
NEFA, mmol/L
|
0.65 (0.04)
|
0.62 (0.06)
|
0.64 (0.06)
|
0.63 (0.04)
|
0.61 (0.05)
|
|
Glucose, mmol/L
|
4.96 (0.16)
|
5.61 (0.20) c
|
5.2 (0.14) b
|
5.42 (0.12) c
|
5.16 (0.10) b
|
|
Insulin, pmol/L
|
64.6 (6.59)
|
69.22 (9.68)
|
47.95 (6.11) a,*
|
84.40 (10.79) a
|
76.31 (11.82)
|
|
HOMA-IR
|
1.15 (0.20)
|
1.33 (0.18)
|
0.92 (0.14) a,*
|
1.64 (0.22) a
|
1.48 (0.25)
|
|
Cholesterol, mmol/L
|
5.27 (0.12)
|
5.52 (0.19)
|
5.14 (0.23)
|
4.74 (0.15) c
|
4.41 (0.16) c
|
|
HDL-cholesterol, mmol/L
|
1.36 (0.03)
|
1.24 (0.09) a
|
1.15 (0.08) b
|
1.21 (0.05) b
|
1.07 (0.05) c, *
|
|
LDL-cholesterol, mmol/L
|
3.19 (0.79)
|
3.28 (0.17)
|
2.96 (0.17)
|
2.71 (0.13) c
|
2.38 (0.13) c
|
|
Triglyceride, mmol/L
|
1.27 (0.9)
|
3.00 (0.47) c
|
3.11 (1.01)
|
2.04 (0.18) c
|
3.24 (1.09) c
|
|
Apolipoprotein AI, g/L
|
1.69 (0.05)
|
1.44 (0.05) c
|
1.26 (0.04) c, **
|
1.40 (0.03) c
|
1.33 (0.04) c
|
|
Alanine aminotransferase, μKat/L
|
0.46 (0.02)
|
0.45 (0.03)
|
0.51 (0.04)
|
0.98 (0.11) c
|
0.97 (0.11) c
|
|
Aspartate aminotransferase, μKat/L
|
0.41 (0.02)
|
0.41 (0.03)
|
0.47 (0.08)
|
0.88 (0.09) c
|
0.88 (0.99) c
|
- Values are the mean and the standard error of the mean (S.E.M.).
- VL indicates HIV-1 viral load; HOMA-IR is homeostasis model assessment-estimated insulin resistance; NEFA is non-esterificated fatty acids.
-
a P < 0.05, b P < 0.01 and c P < 0.001 with respect to control group; * P < 0.05 and ** P = 0.006 with respect to patients with VL < 40 copies/mL in the corresponding group
